Valeant Pharma (VRX) Price Target Lowered to $45 at TD Securities

TD Securities earlier maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and lowered its price target to $45.00 (from $110.00). The change follows updated guidance announced yesterday.

Analyst Lennox Gibbs said, "This latest revision layers on to an already protracted decline in investor confidence. We believe that it could take at least until the Q1/16 release to sufficiently validate Valeant’s 2016/2017 earnings prospects. We are raising our risk rating to SPECULATIVE from High given reduced confidence in the EPS outlook and the company's ability to de-leverage."

"Valeant appears to be caught in a vortex of challenges — including market access hurdles, channel disruption, credibility, and compliance issues," added the analyst. "Although we remain positive regarding the quality of Valeant’s pharmaceutical assets, we expect the near-term uncertainty to obscure the long-term earnings potential of those franchises. Moreover, shares remain vulnerable to new unknowns and headline risk."

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $33.51 yesterday.

You May Also Be Interested In

• Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
• United Airlines (UAL) PT Raised to $153 at UBS Ahead of Q2 Results
• Delta Air Lines (DAL) PT Raised to $107 at UBS Ahead of Q2 Results